[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 35 of about 35
1. Baker SG, Kramer BS: The transitive fallacy for randomized trials: if A bests B and B bests C in separate trials, is A better than C? BMC Med Res Methodol; 2002 Nov 13;2:13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We extended the graphical approach for omitted binary variables that was originally developed to illustrate Simpson's paradox, applying it to hypothetical, but plausible scenarios involving lung cancer screening, treatment for gastric cancer, and antibiotic therapy for clinical pneumonia.
  • In the most dramatic scenario, B bests C in the first trial, A bests B in the second trial, but C bests A at the time of the second trial.
  • CONCLUSION: Even with large sample sizes, combining results from a previous randomized trial of B versus C with results from a new randomized trial of A versus B will not guarantee correct inference about A versus C.
  • A three-arm trial of A, B, and C would protect against this problem and should be considered when the sequential trials are performed in the context of changing secular trends in important omitted variables such as therapy in cancer screening trials.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Lung Neoplasms / mortality. Lung Neoplasms / prevention & control. Mass Screening. Pneumonia / drug therapy. Pneumonia / mortality. Stomach Neoplasms / mortality. Stomach Neoplasms / therapy. Survival Analysis. Survival Rate

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1308-16 [10944552.001]
  • [Cites] J Womens Health Gend Based Med. 2001 Nov;10(9):867-72 [11747681.001]
  • [Cites] Cancer. 1991 Feb 15;67(4 Suppl):1155-64 [1991274.001]
  • [ErratumIn] BMC Med Res Methodol. 2003 Oct 29;3(1):23
  • (PMID = 12429069.001).
  • [ISSN] 1471-2288
  • [Journal-full-title] BMC medical research methodology
  • [ISO-abbreviation] BMC Med Res Methodol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC137603
  •  go-up   go-down


2. Forster J, Sarosiek I, Lin Z, Durham S, Denton S, Roeser K, McCallum RW: Further experience with gastric stimulation to treat drug refractory gastroparesis. Am J Surg; 2003 Dec;186(6):690-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Further experience with gastric stimulation to treat drug refractory gastroparesis.
  • BACKGROUND: Gastric electrical stimulation (GES) has been introduced for patients with gastroparesis refractory to pharmacological therapy.
  • All patients had prolonged gastric retention of a solid meal by scintigraphy at baseline.
  • Body mass index and nutritional parameters were monitored.
  • On average, gastric emptying did not change.
  • Body mass index and body weight increased significantly.
  • CONCLUSIONS: In a large series of patients with gastroparesis, GES significantly improved symptoms and quality of life.
  • [MeSH-major] Electric Stimulation Therapy. Gastroparesis / therapy
  • [MeSH-minor] Adult. Aged. Diabetes Complications. Electrodes, Implanted. Female. Gastric Emptying. Humans. Male. Middle Aged. Postoperative Complications. Prostheses and Implants. Quality of Life. Weight Gain

  • Genetic Alliance. consumer health - Gastroparesis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14672781.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. Piscitelli D, Sanguedolce F, Mattioli E, Parisi G, Fiore MG, Resta L: [Unusual presentation of metastatic osteosarcoma as a giant duodenal polyp. A case report]. Pathologica; 2005 Apr;97(2):88-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: We describe a case of a 27 year old man, who was diagnosed with a grade IV osteoblastic osteosarcoma of the left tibia and submitted to 5 courses of pre-surgical chemotherapy; later he underwent tibial resection with implantation of a prosthesis, followed by 2 further courses of adjuvant chemotherapy.
  • Five years after the patient presented with melena and acute anemia; during endoscopic examination, a large bleeding duodenal polyp was found, so a surgical resection of the gastric antrum, duodenum, head of the pancreas, main bile ducts and gallbladder was performed.
  • RESULTS: Microscopically, the tumor mass showed a mostly fasciculated architecture, composed of spindle and epithelioid cells in a scarce fibromyxoid stroma, featuring large areas of coagulative necrosis and small foci of sclerohyalinosis.
  • Tumor cells featured large vesciculous nuclei, with a few prominent nucleoli; no foci of osteoid matrix were detectable.
  • Due to alteration of the natural history of the tumor induced by multiagent chemotherapy, the rate of metastases of osteosarcoma to unusual sites has been increasing.
  • Both the histological features and the immunohistochemical findings were not suggestive for osteosarcoma metastases because the tumor appeared dedifferentiated; in our case the combination of electron microscopy and clinical history played a pivotal role to establish the final diagnosis.


Advertisement
4. Patel VG, Eltayeb OM, Henderson VJ, Lyons R, Martin D, Hamami A, Fortson JK, Weaver WL: Primary duodenal low-grade mucosa-associated lymphoid tissue lymphoma presenting with outlet obstruction. Am Surg; 2004 Jul;70(7):613-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary duodenal low-grade mucosa-associated lymphoid tissue lymphoma presenting with outlet obstruction.
  • Low-grade lymphoma arising in mucosa-associated lymphoid tissue (MALT) of the duodenum represents a very rare neoplasm.
  • A large atypical ulcer with narrowing of the duodenum beyond the bulb was seen on endoscopy.
  • Abdominal CT scan revealed a mass in either the duodenum or head of the pancreas.
  • An endoscopic retrograde cholangiopancreatography (ERCP) was performed, which revealed a normal pancreatic duct with a large calculus in the common bile duct, which was extracted after sphincterotomy.
  • The patient developed severe nausea, vomiting, and fullness after meals.
  • The patient underwent pancreaticoduodectomy for a neoplastic mass causing duodenal obstruction.
  • Celiac, peripancreatic, pelvic, and cervical nodes were also involved with tumor.
  • The patient was postoperatively treated with chemotherapy for stage IV disease.
  • [MeSH-major] Duodenal Neoplasms / complications. Duodenal Neoplasms / surgery. Gastric Outlet Obstruction / surgery. Lymphoma, B-Cell, Marginal Zone / complications. Lymphoma, B-Cell, Marginal Zone / surgery
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Male

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15279185.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Miyazaki O, Hayakawa M, Nosaka S, Baba K, Iida S, Imanishi Y, Enomoto T, Ihara A, Tanaka I, Hagiwara M: [A case of biloma caused by early complications of hepatic artery infusion chemotherapy]. Gan To Kagaku Ryoho; 2000 May;27(5):749-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of biloma caused by early complications of hepatic artery infusion chemotherapy].
  • We report a 70-year-old male who had biloma as an early complication of hepatic artery infusion chemotherapy.
  • The patient had a history of subtotal gastrectomy for a advanced gastric cancer.
  • Two years after the primary operation on the stomach, a solitary metastatic liver tumor was indicated by follow-up abdominal CT, and a segmental hepatectomy was performed.
  • Soon after the hepatectomy, intraarterial catheter placement was performed via the left subclavian artery for preventive chemotherapy.
  • Infusion chemotherapy of 10.5 g 5-FU and 75 mg CDDP was administered for a month, during which time the patient had liver dysfunction, fever, tenderness, and abdominal fullness.
  • Abdominal CT revealed a large low density mass at a lateral segment of the liver which could not be seen on the previous CT image.
  • The present case is thought to be of an early and rare complication of hepatic artery infusion chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bile. Infusion Pumps, Implantable / adverse effects. Infusions, Intra-Arterial / adverse effects. Liver Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10832446.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; CF regimen
  •  go-up   go-down


6. Mizuno N, Naruse S, Kitagawa M, Ishiguro H, Ito O, Ko SB, Yoshikawa T, Tanahashi C, Ito M, Hayakawa T: Insulinoma with subsequent association of Zollinger-Ellison syndrome. Intern Med; 2001 May;40(5):386-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 67-year-old woman was first admitted to our hospital for an abdominal mass.
  • Abdominal computed tomography (CT) revealed a large pancreatic tumor, which was then diagnosed as an unresectable pancreatic adenocarcinoma.
  • Chemotherapy with 5-fluorouracil and doxorubicin was performed.
  • Plasma gastrin level was 1,960 pg/ml at that time.
  • Gastric hypersecretion was well controlled with a proton pump inhibitor (lansoprazole) but she died of widespread cancer dissemination 8 years after her first admission.
  • [MeSH-minor] Aged. Cholangiopancreatography, Endoscopic Retrograde. Fatal Outcome. Female. Humans. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Insulinoma.
  • Genetic Alliance. consumer health - Zollinger-Ellison syndrome.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Intern Med 2001 Jun;40(6):553
  • (PMID = 11393407.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


7. Raz I, Eldor R, Cernea S, Shafrir E: Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. Diabetes Metab Res Rev; 2005 Jan-Feb;21(1):3-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present multiple findings on derangements in lipid metabolism in type 2 diabetes.
  • The obesity often associated with type 2 diabetes is mainly central, resulting in the overload of abdominal adipocytes with TG and reducing fat depot capacity to protect other tissues from utilizing a large proportion of dietary fat.
  • The enlarged visceral adipocytes are flooding the portal circulation with free fatty acids (FFA) at metabolically inappropriate time, when FFA should be oxidized, thus exposing nonadipose tissues to fat excess.
  • This situation, based on a large number of observations in humans and experimental animals, confirms that peripheral adipose tissue is closely regulated, performing a vital role of buffering fluxes of FFA in the circulation.
  • The central adipose tissues tend to upset this balance by releasing large amounts of FFA.
  • Indirect treatment consists of the compliant application of drastic lifestyle change comprising both diet and exercise and pharmacotherapy that reduces mesenteric fat mass and activity.
  • Next comes pharmacotherapy including acarbose, metformin, PPARgamma, or PPARgammaalpha agonists, statins and orlistat, estrogens in postmenopausal women or testosterone in men.
  • Among surgical procedures, gastric bypass has been proven to produce beneficial results in advance of other surgical techniques, the evidence basis of which still needs strengthening.
  • [MeSH-minor] Animals. Biological Transport. Fatty Acids, Nonesterified / metabolism. Humans. Hypoglycemic Agents / therapeutic use. Islets of Langerhans / pathology. Life Style. Obesity / metabolism. Triglycerides / metabolism

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2004 John Wiley & Sons, Ltd.
  • (PMID = 15386813.001).
  • [ISSN] 1520-7552
  • [Journal-full-title] Diabetes/metabolism research and reviews
  • [ISO-abbreviation] Diabetes Metab. Res. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Fatty Acids, Nonesterified; 0 / Hypoglycemic Agents; 0 / Triglycerides
  • [Number-of-references] 133
  •  go-up   go-down


8. Yang Y, Lim SK, Choong LY, Lee H, Chen Y, Chong PK, Ashktorab H, Wang TT, Salto-Tellez M, Yeoh KG, Lim YP: Cathepsin S mediates gastric cancer cell migration and invasion via a putative network of metastasis-associated proteins. J Proteome Res; 2010 Sep 3;9(9):4767-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cathepsin S mediates gastric cancer cell migration and invasion via a putative network of metastasis-associated proteins.
  • Substances released by gastric cancer cells have not being profiled in a proteome-wide manner.
  • ITRAQ-based tandem mass spectrometry was employed to quantify proteins secreted by HFE145 normal, MKN7 well-differentiated, and MKN45 poorly differentiated gastric cancer cell lines.
  • Further examination of 16 gastric cell lines and 115 clinical samples validated the up-regulation of CTSS expression in gastric cancer.
  • Silencing CTSS expression suppressed the migration and invasion of gastric cancer cells in vitro.
  • Proteome-wide comparative secretomes of normal and gastric cancer cells were produced that constitute a useful resource for gastric cancer research.
  • CTSS was demonstrated to play novel roles in gastric cancer cell migration and invasion, putatively via a network of proteins associated with cell migration, invasion, or metastasis.
  • Cathepsin S is member of a large group of extracellular proteases, which are attractive drug targets.
  • The implicated role of CTSS in gastric cancer metastasis provides an opportunity to test existing compounds against CTSS for adjuvant therapy and/or treatment of metastatic gastric cancers.
  • [MeSH-minor] Cell Line, Tumor. Humans. Isotope Labeling. Neoplasm Invasiveness. Proteomics / methods. Reproducibility of Results. Signal Transduction. Tandem Mass Spectrometry

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Proteome Res. 2010 Dec 3;9(12):6801. muliple author names corrected
  • (PMID = 20812763.001).
  • [ISSN] 1535-3907
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; EC 3.4.- / Cathepsins; EC 3.4.22.27 / cathepsin S
  •  go-up   go-down


9. Sukpanichnant S, Udomsakdi-Auewarakul C, Ruchutrakool T, Leelakusolvong S, Boonpongmanee S, Chinswangwatanakul V: Gastrointestinal lymphoma in Thailand: a clinicopathologic analysis of 120 cases at Siriraj Hospital according to WHO classification. Southeast Asian J Trop Med Public Health; 2004 Dec;35(4):966-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mass lesions were observed in both groups (72.1% vs 56.3%).
  • The most common type of lymphoma in both groups was diffuse large B-cell lymphoma.
  • Lymphoepithelial lesions (LEL) were not significantly different between the two groups (58.2% vs 42.9%), but Helicobacterpylori infection was significantly associated with primary gastric lymphoma (p < 0.0001).
  • The treatment of choice for localized primary GI lymphoma is controversial.
  • Complete surgical resection may increase the chance of complete remission, but mortality and relapse rates might be higher than those observed with combination chemotherapy alone.
  • LEL is not indicative of primary GI lymphoma, but H. pylori infection is closely associated with primary gastric lymphoma.
  • A prospective study to determine the treatment of choice for localized GI lymphoma is needed.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Retrospective Studies. Thailand

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15916100.001).
  • [ISSN] 0125-1562
  • [Journal-full-title] The Southeast Asian journal of tropical medicine and public health
  • [ISO-abbreviation] Southeast Asian J. Trop. Med. Public Health
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


10. Misra SP, Dwivedi M, Misra V: Endoscopic management of a new entity-plastobezoar: a case report and review of literature. World J Gastroenterol; 2006 Nov 7;12(41):6730-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a child aged 11 years who ingested large amounts of plastic material used for knitting chairs and charpoys.
  • The conglomerate of plastic threads, entrapped food material and other debris, formed a huge mass occupying the whole stomach.
  • Chronic irritation of the gastric antral mucosa led to ulceration and formation of hyperplastic polyps.
  • [MeSH-minor] 2-Pyridinylmethylsulfinylbenzimidazoles / therapeutic use. Anti-Ulcer Agents / therapeutic use. Child. Gastric Mucosa / pathology. Humans. Male. Polyps / drug therapy. Polyps / etiology. Polyps / pathology. Stomach Diseases / drug therapy. Stomach Diseases / etiology. Stomach Diseases / pathology

  • Hazardous Substances Data Bank. PANTOPRAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] An Esp Pediatr. 1999 Oct;51(4):402-4 [10690235.001]
  • [Cites] World J Gastroenterol. 2005 Mar 28;11(12):1813-7 [15793871.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2000 Aug;10(4):243-5 [10961755.001]
  • [Cites] Gastrointest Endosc. 2000 Sep;52(3):404-8 [10968861.001]
  • [Cites] J Postgrad Med. 2000 Apr-Jun;46(2):94-5 [11013473.001]
  • [Cites] AJR Am J Roentgenol. 2001 Jul;177(1):65-9 [11418400.001]
  • [Cites] Nephron. 2002 Mar;90(3):352-4 [11867960.001]
  • [Cites] J Pediatr Surg. 2002 Sep;37(9):1363-4 [12194136.001]
  • [Cites] South Med J. 1985 Dec;78(12):1520 [4071186.001]
  • [Cites] Rev Gastroenterol Mex. 1985 Apr-Jun;50(2):147-9 [4089453.001]
  • [Cites] Med J Aust. 1986 Dec 1-15;145(11-12):613-4 [3540541.001]
  • [Cites] J Pediatr Surg. 1987 Feb;22(2):184-5 [3820024.001]
  • [Cites] West J Med. 1988 Aug;149(2):220-3 [3247739.001]
  • [Cites] Dig Dis Sci. 1993 Aug;38(8):1422-5 [8344097.001]
  • [Cites] Postgrad Med J. 1993 Aug;69(814):659-60 [8234118.001]
  • [Cites] Br J Surg. 1994 Jul;81(7):1000-1 [7922045.001]
  • [Cites] Zhonghua Nei Ke Za Zhi. 1994 Mar;33(3):172-4 [7805524.001]
  • [Cites] Dig Dis. 1995 Nov-Dec;13(6):356-64 [8590522.001]
  • [Cites] Am J Gastroenterol. 1996 Jun;91(6):1285-6 [8651205.001]
  • [Cites] Gastrointest Endosc Clin N Am. 1996 Jul;6(3):605-19 [8803570.001]
  • [Cites] Endoscopy. 1996 May;28(4):399 [8813513.001]
  • [Cites] Postgrad Med J. 1997 Apr;73(858):243-4 [9156131.001]
  • [Cites] Trop Gastroenterol. 1997 Jul-Sep;18(3):135 [9385864.001]
  • [Cites] J Pediatr Surg. 1998 Apr;33(4):663-5 [9574777.001]
  • [Cites] Endoscopy. 1998 May;30(4):371-4 [9689511.001]
  • [Cites] Endoscopy. 1999 Jun;31(5):386-8 [10433049.001]
  • [Cites] Ann Pharmacother. 2000 Jul-Aug;34(7-8):862-4 [10928396.001]
  • (PMID = 17075994.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / 2-Pyridinylmethylsulfinylbenzimidazoles; 0 / Anti-Ulcer Agents; 0 / Plastics; D8TST4O562 / pantoprazole
  • [Number-of-references] 27
  • [Other-IDs] NLM/ PMC4125686
  •  go-up   go-down


11. Fulignati C, Pantaleo P, Cipriani G, Turrini M, Nicastro R, Mazzanti R, Neri B: An uncommon clinical presentation of retroperitoneal non-Hodgkin lymphoma successfully treated with chemotherapy: a case report. World J Gastroenterol; 2005 May 28;11(20):3151-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An uncommon clinical presentation of retroperitoneal non-Hodgkin lymphoma successfully treated with chemotherapy: a case report.
  • We report the case of a patient affected by an extra-nodal non-Hodgkin lymphoma presenting as a unique, large retroperitoneal mass with an unusual clinical presentation mimicking gastric peptic or neoplastic disease.
  • The patient was successfully treated with a first generation therapy, CHOP modified regimen (cyclophosphamide 600 mg/m2 intravenously on d 1, epirubicin 55 mg/m2 intravenously on d 1, vincristine 1.2 mg/m2 intravenously on d 1, prednisone 60 mg/m2 on d 1-5), and a complete response was achieved.
  • The (18)F-fluorodeoxyglucose positron emission tomography was used to assess the therapy outcome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy. Prednisolone / therapeutic use. Retroperitoneal Neoplasms / drug therapy. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15918208.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  • [Other-IDs] NLM/ PMC4305858
  •  go-up   go-down


12. Kurosawa H, Matsunaga T, Shimaoka H, Sato Y, Kuwashima S, Sugita K, Hagane K, Eguchi M: Burkitt lymphoma associated with large gastric folds, pancreatic involvement, and biliary tract obstruction. J Pediatr Hematol Oncol; 2002 May;24(4):310-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt lymphoma associated with large gastric folds, pancreatic involvement, and biliary tract obstruction.
  • Large gastric folds in adults are seen in many benign and malignant conditions, but they are rare in children with malignant diseases such as non-Hodgkin lymphoma.
  • The authors report a patient with non-Hodgkin lymphoma who had large gastric folds and jaundice as the initial symptoms.
  • A standard barium upper gastrointestinal series showed large gastric folds in the entire stomach.
  • Magnetic resonance imaging showed a typical diffuse infiltrating type of pancreatic lymphoma.
  • Because complete bilateral lower limb paralysis developed as a result of the epidural soft tissue mass, laminectomy and tumor resection were performed and a diagnosis of disseminated Burkitt lymphoma was established.
  • After completing 6 months of chemotherapy, the patient has been disease-free without neurologic complications for 2.5 years.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Cholestasis / diagnosis. Gastric Mucosa / pathology. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11972102.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


13. Opatrny L, Prichard R, Snell L, Maclean JD: Death related to albendazole-induced pancytopenia: case report and review. Am J Trop Med Hyg; 2005 Mar;72(3):291-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Albendazole is a benzimidazole with wide spectrum coverage as an antiparasitic drug.
  • We report the case of a patient who died with severe prolonged pancytopenia beginning during the third week of therapy for a pulmonary echinococcal cyst.
  • This case was a 68-year-old man who presented with a large cystic lung mass.
  • Albendazole sulfoxide peak dose and half life are significantly prolonged by liver disease and concomitant administration of certain drugs.
  • Frequent serial monitoring of blood counts and cessation of medication with any evidence of marrow toxicity in such patients is warranted.
  • [MeSH-major] Albendazole / adverse effects. Anthelmintics / adverse effects. Echinococcosis / drug therapy. Pancytopenia / chemically induced
  • [MeSH-minor] Aged. Autopsy. Biopsy. Esophageal and Gastric Varices / parasitology. Fatal Outcome. Humans. Liver Cirrhosis / parasitology. Liver Cirrhosis / pathology. Male

  • Hazardous Substances Data Bank. ALBENDAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15772324.001).
  • [ISSN] 0002-9637
  • [Journal-full-title] The American journal of tropical medicine and hygiene
  • [ISO-abbreviation] Am. J. Trop. Med. Hyg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthelmintics; F4216019LN / Albendazole
  •  go-up   go-down


14. Kokki H, Rasanen I, Reinikainen M, Suhonen P, Vanamo K, Ojanperä I: Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children. Clin Pharmacokinet; 2004;43(9):613-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacokinetics of oxycodone after intravenous, buccal, intramuscular and gastric administration in children.
  • OBJECTIVE: To evaluate the pharmacokinetics of four administration routes of oxycodone parenteral liquid (10 mg/mL), single intravenous and intramuscular injections and buccal and gastric administration, in children.
  • Regular blood samples were collected up to 12 hours, and plasma was analysed for oxycodone using gas chromatography-mass spectrometry (limit of quantification 1 microg/L).
  • RESULTS: The peak drug concentration observed was 57-110 (mean 82) microg/L after intravenous administration, 23-54 (34) microg/L after intramuscular administration, 3.9-14 (9.8) microg/L after buccal administration and 1.7-15 (9.2) microg/L after gastric administration.
  • The time to peak concentration was 2-30 (16) minutes in the intramuscular group, 30-480 (221) minutes in the buccal group and 60-360 (193) minutes in the gastric group.
  • The terminal elimination half-lives were closely similar in the four groups: 124-208 (163) minutes in the intravenous group, 162-227 (150) minutes in the intramuscular group, 73-234 (150) minutes in the buccal group and 80-246 (147) minutes in the gastric group.
  • Area under the concentration-time curve (AUC) was 5037-8954 (6612) microg x min/L in the intravenous group, 3084-5524 (4473) microg x min/L in the intramuscular group, 1444-5560 (3658) microg x min/L in the buccal group and 692-3843 (2436) microg x min/L in the gastric group.
  • The estimated bioavailability (AUC/mean intravenous AUC) of intramuscular oxycodone was 0.47-0.84 (0.68), that of buccal oxycodone 0.22-0.84 (0.55) and that of gastric oxycodone 0.10-0.58 (0.37).
  • Intramuscular administration provides relatively constant drug absorption, but after buccal and gastric administration the interindividual variation in the rate and extent of absorption is large.
  • [MeSH-minor] Administration, Buccal. Administration, Oral. Biological Availability. Child. Child, Preschool. Female. Humans. Infant. Injections, Intramuscular. Injections, Intravenous. Intubation, Gastrointestinal. Male. Pain, Postoperative / drug therapy. Prospective Studies. Time Factors

  • Hazardous Substances Data Bank. OXYCODONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Anaesthesiol. 1994 May;11(3):221-30 [7914167.001]
  • [Cites] J Forensic Sci. 1998 Nov;43(6):1220-4 [9846400.001]
  • [Cites] J Pharmacol Exp Ther. 1978 Oct;207(1):92-100 [359779.001]
  • [Cites] Acta Anaesthesiol Scand. 1998 May;42(5):576-80 [9605375.001]
  • [Cites] Acta Anaesthesiol Scand. 1991 Oct;35(7):642-6 [1785245.001]
  • [Cites] Clin Pharmacokinet. 2003;42(4):373-9 [12648027.001]
  • [Cites] Eur J Clin Pharmacol. 2001 Nov;57(9):643-7 [11791893.001]
  • [Cites] Clin Pharmacol Ther. 1988 Sep;44(3):335-42 [2458208.001]
  • [Cites] Br J Clin Pharmacol. 1992 Jun;33(6):617-21 [1389934.001]
  • [Cites] Br J Anaesth. 1998 Jul;81(1):3-7 [9771266.001]
  • [Cites] Lancet. 1959 Oct 10;2(7102):544-6 [13855594.001]
  • [Cites] Ther Drug Monit. 1992 Dec;14(6):479-84 [1485370.001]
  • [Cites] Clin Chem. 1997 Jun;43(6 Pt 1):1029-32 [9191557.001]
  • [Cites] J Clin Pharmacol. 2000 Apr;40(4):354-9 [10761162.001]
  • [Cites] Acta Anaesthesiol Scand. 1997 Feb;41(2):309-12 [9062618.001]
  • [Cites] Acta Anaesthesiol Scand. 1998 Oct;42(9):1070-5 [9809090.001]
  • [Cites] Acta Anaesthesiol Scand. 1998 Mar;42(3):323-8 [9542560.001]
  • [Cites] Br J Clin Pharmacol. 1994 Jul;38(1):71-6 [7605420.001]
  • [Cites] J Pain Symptom Manage. 1993 Feb;8(2):63-7 [8492004.001]
  • [Cites] JAMA. 2000 Dec 20;284(23):3043-5 [11122593.001]
  • (PMID = 15217304.001).
  • [ISSN] 0312-5963
  • [Journal-full-title] Clinical pharmacokinetics
  • [ISO-abbreviation] Clin Pharmacokinet
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Analgesics, Opioid; CD35PMG570 / Oxycodone
  •  go-up   go-down


15. Lasota J, Nordling S, Miettinen M: Testicular diffuse large cell lymphoma with tubule preservation--molecular genetic evidence of transformation from previous follicular lymphoma. Virchows Arch; 2000 Mar;436(3):276-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Testicular diffuse large cell lymphoma with tubule preservation--molecular genetic evidence of transformation from previous follicular lymphoma.
  • Testicular lymphomas usually occur in older men and are mostly diffuse large B-cell lymphomas (DLBL).
  • This report details a testicular large cell lymphoma, which was proven to be large cell transformation of a low-grade follicular lymphoma biopsied 8 years earlier.
  • Initially, a 38-year old man was diagnosed with cervical lymphadenopathy, and biopsy was interpreted as reactive follicular hyperplasia; no treatment was given, and the lymphadenopathy resolved spontaneously.
  • Eight years later, the patient underwent surgery for a left testicular mass and gastroscopy for gastric symptoms.
  • The patient died 7 months later with evidence for intra-abdominal and central nervous system lymphoma after a brief but temporary response to M-BACOD chemotherapy.
  • Orchiectomy specimen and gastroscopic biopsy showed diffuse large B-cell lymphoma (CD20+), which infiltrated between well-preserved tubules in the testis.
  • Histological comparison with 20 testicular lymphomas without previous lymphoma showed tubule infiltration in all cases, suggesting that the tubule-preserving infiltration pattern could be a histological marker for secondary lymphoma involvement in testis.
  • The earlier follicular lymphoma and the subsequent diffuse large cell lymphoma were analyzed using polymerase chain reaction and showed identical sequences of the t(14;18) translocation and immunoglobulin heavy chain gene rearrangement.
  • However, the transformed diffuse large cell lymphoma had no intraclonal variation, with the sequence matching with one of the subclones from the low-grade follicular lymphoma.
  • These results confirm that the large cell transformation of follicular lymphoma occurs in a single follicular lymphoma cell.
  • This case also indicates that the selection of the transformed clone can be part of the natural history of disease and can occur without exposure to chemotherapy.
  • [MeSH-major] Cell Transformation, Neoplastic. Genes, Immunoglobulin. Lymphoma, Follicular / genetics. Lymphoma, Follicular / pathology. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / pathology. Testicular Neoplasms / genetics. Testicular Neoplasms / pathology

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10782887.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains
  •  go-up   go-down


16. Rudzki Z, Rucińska M, Jurczak W, Skotnicki AB, Maramorosz-Kurianowicz M, Mruk A, Piróg K, Utych G, Bodzioch P, Srebro-Stariczyk M, Włodarska I, Stachura J: ALK-positive diffuse large B-cell lymphoma: two more cases and a brief literature review. Pol J Pathol; 2005;56(1):37-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive diffuse large B-cell lymphoma: two more cases and a brief literature review.
  • Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (DLBCL) is a rare, recently defined tumor distinct in many aspects from ALK-positive anaplastic large cell lymphoma (ALCL).
  • A 48-year old man presented with a large upper neck mass growing slowly over 18 months.
  • Histologically the tumor was diagnosed as an ALK-positive diffuse large B-cell lymphoma. with plasmablastic features.
  • Large, frequently intrasinusoidal tumor cells expressed CD138, EMA, weakly IgA and kappa, but were negative for other B-cell markers, T-cell markers and CD30.
  • The patient died of massive bleeding from his decomposing tumor 3 months after the diagnosis.
  • A 49-year old man complaining of abdominal pain revealed abdominal lymphadenomegaly and a gastric infiltrate, involving the deep portions of the gastric wall.
  • The tumor showed immunoblastic/anaplastic morphology, with some Reed-Sternberg-like cells positive for ALK.
  • The tumor demonstrated similar "null" B/T phenotype with positivity for IgA, lambda, EMA and LCA.
  • The patient (stage IVB) currently undergoes chemotherapy.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Protein-Tyrosine Kinases / metabolism
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biomarkers, Tumor / metabolism. Cyclophosphamide / administration & dosage. DNA, Neoplasm / analysis. Doxorubicin / administration & dosage. Fatal Outcome. Humans. In Situ Hybridization, Fluorescence. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Receptor Protein-Tyrosine Kinases. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15921012.001).
  • [ISSN] 1233-9687
  • [Journal-full-title] Polish journal of pathology : official journal of the Polish Society of Pathologists
  • [ISO-abbreviation] Pol J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 17
  •  go-up   go-down


17. Martino A, Festa P, La Rocca F, Romagnuolo G, Bartone G, Di Muria A, Napolitano G, De Sena G, Martino R, Nappi O: [Abdominal lymphoma with abscess and thoracic perforation: en-bloc resection]. Ann Ital Chir; 2002 Jul-Aug;73(4):445-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors compare a rare case of acute onset Gastric Lymphoma with that present in the literature.
  • On CT scan an opacity of the pleura and a subtotal collapse of the left lung associated with a mass infiltrating the diaphragm, the gastric fundus and pancreas were seen.
  • The abdominal mass infiltrating the stomach, the spleen and the left thorax was resected en-bloc by laparotomy.
  • Surgery can be necessary, sometime curative in gastric lymphomas while long term result and quality of life could be improved by chemotherapy.
  • [MeSH-major] Abdominal Abscess / etiology. Lymphoma, Large B-Cell, Diffuse / complications. Stomach Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12661236.001).
  • [ISSN] 0003-469X
  • [Journal-full-title] Annali italiani di chirurgia
  • [ISO-abbreviation] Ann Ital Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


18. Parvez T, Behani A, Ali A: Primary gastric lymphoma. J Coll Physicians Surg Pak; 2007 Jan;17(1):36-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastric lymphoma.
  • OBJECTIVE: To evaluate the clinico-pathological status of Primary Gastric Lymphoma (PGL) at presentation in King Fahad Hospital, Madina Munawra, Kingdom of Saudi Arabia (KSA).
  • According to the treatment modality, different groups were established.
  • Any other histopathological type was excluded from the study.
  • Most common presenting symptoms were epigastric or upper abdominal pain with or without mass.
  • Diffuse large cell lymphoma was found in 12 (55%), poorly differentiated lymphoma in 3 (14%) and diffuse mixed in 7 (32%).
  • Sixteen (73%) patients underwent chemotherapy with some surgical resection, in 5 (23%) surgical procedure was palliative bypass and 11 (50%) had partial gastrectomy.
  • Three (14%) had only chemotherapy after endoscopic biopsy.
  • CONCLUSION: PGL is usually of NHL type, presenting in the sixth decade, and can be successfully treated with both surgery and chemotherapy when patients presented at stage II.
  • Chemotherapy after sub-total gastrectomy or biopsy was the best treatment option.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Lymphoma, Non-Hodgkin / therapy. Stomach Neoplasms / diagnosis. Stomach Neoplasms / therapy
  • [MeSH-minor] Abdominal Pain / etiology. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Gastrectomy. Humans. Male. Middle Aged. Prednisone / therapeutic use. Saudi Arabia. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17204218.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


19. Bilici A, Ozguroglu M, Tuzuner N, Goksel S, Turna H: Primary diffuse large B cell lymphoma of the breast eight years after the diagnosis of gastric MALT lymphoma: report of first case. Arch Gynecol Obstet; 2010 Nov;282(5):587-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary diffuse large B cell lymphoma of the breast eight years after the diagnosis of gastric MALT lymphoma: report of first case.
  • Primary breast lymphoma (PBL) is an uncommon type of extranodal non-Hodgkin's lymphoma (NHL), accounting for approximately 1% of all extranodal NHL.
  • Diffuse large B cell lymphoma (DLBCL) is the most frequent histology.
  • Both primary mucosa-associated lymphoid tissue (MALT) lymphoma of the breast and its relapse have been documented previously.
  • We report on a 63-year-old woman with primary DLBCL of the breast which was diagnosed 8 years after gastric MALT lymphoma.
  • Following chemotherapy, complete response was obtained.
  • We suggest that for women presenting with a breast mass who received cytotoxic treatment for the other lymphoma, PBL should be considered in the differential diagnosis of the breast mass together with primary breast carcinoma.
  • [MeSH-major] Breast Neoplasms / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Diagnosis, Differential. Female. Humans. Middle Aged


20. Small DS, Farid NA, Payne CD, Konkoy CS, Jakubowski JA, Winters KJ, Salazar DE: Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel. Clin Pharmacokinet; 2010 Dec;49(12):777-98
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pras-AM exposure was greater in subjects aged ≥ 75 years, but exposure differences were not as large as those for bodyweight.
  • Prasugrel has few clinically significant drug-drug interactions.
  • Potent CYP3A inhibitors, gastric acid suppressants and food have been shown to reduce the rate of formation of Pras-AM but not its overall exposure.
  • Prior treatment with clopidogrel did not influence tolerability to prasugrel and did not appear to alter IPA during prasugrel treatment.
  • The inhibition of CYP2B6 is potentially clinically significant only for drugs that have a narrow therapeutic window and have CYP2B6 as the primary elimination pathway.
  • [MeSH-minor] Acute Coronary Syndrome / complications. Acute Coronary Syndrome / therapy. Angioplasty, Balloon, Coronary / methods. Drug Interactions. Humans. Platelet Aggregation / drug effects. Prasugrel Hydrochloride

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pharmacol Exp Ther. 1992 Nov;263(2):840-5 [1359120.001]
  • [Cites] Lancet. 1996 Nov 16;348(9038):1329-39 [8918275.001]
  • [Cites] Ann Intern Med. 2007 Mar 20;146(6):434-41 [17371888.001]
  • [Cites] Am J Cardiol. 2006 Nov 20;98(10A):4N-10N [17097417.001]
  • [Cites] Drug Metab Dispos. 2006 May;34(5):880-6 [16467132.001]
  • [Cites] Circulation. 2010 Mar 16;121(10):1188-99 [20194878.001]
  • [Cites] Lancet. 2008 Apr 19;371(9621):1353-63 [18377975.001]
  • [Cites] Nat Rev Cardiol. 2009 Apr;6(4):273-82 [19352331.001]
  • [Cites] Circulation. 2004 Jun 29;109 (25):3171-5 [15184279.001]
  • [Cites] J Am Coll Cardiol. 2007 Apr 10;49(14):1505-16 [17418288.001]
  • [Cites] Pharmacotherapy. 2007 Apr;27(4):553-63 [17381383.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2009 Apr;29(4):449-57 [19023091.001]
  • [Cites] J Pharmacol Exp Ther. 2004 Jan;308(1):189-97 [14563790.001]
  • [Cites] Clin Pharmacol Ther. 2005 Jun;77(6):553-9 [15961986.001]
  • [Cites] N Engl J Med. 1996 Apr 25;334(17):1084-9 [8598866.001]
  • [Cites] Xenobiotica. 2007 Jul;37(7):788-801 [17620223.001]
  • [Cites] Thromb Haemost. 2009 Jul;102(1):7-14 [19572061.001]
  • [Cites] Drug Metab Dispos. 2002 May;30(5):488-93 [11950776.001]
  • [Cites] Eur J Clin Pharmacol. 2010 Feb;66(2):127-35 [19888568.001]
  • [Cites] Thromb Haemost. 2008 Jan;99(1):215-22 [18217157.001]
  • [Cites] Thromb Haemost. 2005 Sep;94(3):593-8 [16268477.001]
  • [Cites] J Cardiovasc Pharmacol. 2007 Nov;50(5):555-62 [18030066.001]
  • [Cites] J Clin Pharmacol. 2011 Mar;51(3):321-32 [20410452.001]
  • [Cites] Am Heart J. 2007 Jan;153(1):66.e9-16 [17174640.001]
  • [Cites] N Engl J Med. 2001 Aug 16;345(7):494-502 [11519503.001]
  • [Cites] Curr Med Res Opin. 2008 Aug;24(8):2251-7 [18786302.001]
  • [Cites] Pharmacotherapy. 2008 Dec;28(12 ):1483-94 [19025429.001]
  • [Cites] Am J Cardiovasc Drugs. 2006;6(2):77-86 [16555861.001]
  • [Cites] Am Heart J. 2006 Oct;152(4):627-35 [16996826.001]
  • [Cites] J Clin Pharm Ther. 2009 Oct;34(5):585-94 [19744014.001]
  • [Cites] Platelets. 2008 Jun;19(4):275-81 [18569863.001]
  • [Cites] Eur J Biochem. 1994 Oct 1;225(1):21-7 [7925440.001]
  • [Cites] J Cardiovasc Pharmacol. 2007 Mar;49(3):167-73 [17414229.001]
  • [Cites] JAMA. 2002 Nov 20;288(19):2411-20 [12435254.001]
  • [Cites] Thromb Haemost. 2008 Feb;99(2):409-15 [18278193.001]
  • [Cites] Drug Metab Dispos. 2007 Jul;35(7):1096-104 [17403916.001]
  • [Cites] Eur Heart J. 2009 Jul;30(14 ):1744-52 [19429918.001]
  • [Cites] Lancet. 2005 Nov 5;366(9497):1607-21 [16271642.001]
  • [Cites] Circulation. 2007 Dec 18;116(25):2923-32 [18056526.001]
  • [Cites] J Clin Pharmacol. 2008 Apr;48(4):475-84 [18303127.001]
  • [Cites] Drug Metab Dispos. 2008 Jul;36(7):1227-32 [18372401.001]
  • [Cites] Clin Pharmacokinet. 2003;42(9):819-50 [12882588.001]
  • [Cites] JAMA. 2005 Sep 14;294(10):1224-32 [16143698.001]
  • [Cites] Drug Metab Dispos. 2006 Apr;34(4):600-7 [16415119.001]
  • [Cites] J Am Coll Cardiol. 2008 May 27;51(21):2028-33 [18498956.001]
  • [Cites] J Pharmacokinet Pharmacodyn. 2008 Dec;35(6):593-618 [19023649.001]
  • [Cites] Platelets. 2009 Aug;20(5):316-27 [19637095.001]
  • [Cites] Drug Metab Dispos. 2007 Jun;35(6):917-21 [17353347.001]
  • [Cites] Clin Pharmacol Ther. 2009 Feb;85(2):173-81 [18987624.001]
  • [Cites] Br J Surg. 1973 Aug;60(8):646-9 [4541913.001]
  • [Cites] BMJ. 2002 Jan 12;324(7329):71-86 [11786451.001]
  • [Cites] J Clin Pharmacol. 2008 Jan;48(1):53-9 [18094219.001]
  • [Cites] Br J Anaesth. 2001 Sep;87(3):435-40 [11517128.001]
  • [Cites] Clin Ther. 2010 Feb;32(2):365-79 [20206794.001]
  • [Cites] Life Sci. 2007 Aug 23;81(11):924-32 [17764701.001]
  • [Cites] Cardiovasc Drug Rev. 2007 Winter;25(4):357-74 [18078435.001]
  • [Cites] J Thromb Haemost. 2006 Mar;4(3):542-9 [16371119.001]
  • [Cites] Clin Pharmacol Ther. 2007 May;81(5):735-41 [17361128.001]
  • [Cites] Circulation. 2009 Jan 27;119(3):480-6 [19171871.001]
  • [Cites] Am J Health Syst Pharm. 2008 Jul 1;65(13 Suppl 5):S1-5; quiz S16-8 [18574019.001]
  • [Cites] Thromb Res. 2007;120(3):323-36 [17239428.001]
  • [Cites] J Pharmacol Exp Ther. 1993 Sep;266(3):1614-9 [8103797.001]
  • [Cites] J Thromb Haemost. 2007 Dec;5(12 ):2429-36 [17900275.001]
  • [Cites] Drug Metab Dispos. 2000 Oct;28(10):1222-30 [10997944.001]
  • [Cites] Drugs Aging. 2009;26(9):781-90 [19728751.001]
  • [Cites] J Clin Pharm Ther. 2009 Oct;34(5):575-83 [19744013.001]
  • [Cites] N Engl J Med. 2007 Nov 15;357(20):2078-81 [17982183.001]
  • [Cites] J Clin Pharmacol. 2009 Aug;49(8):984-98 [19546250.001]
  • [Cites] J Am Coll Cardiol. 2006 Nov 7;48(9):1742-50 [17084243.001]
  • [Cites] Chem Res Toxicol. 1992 Jan-Feb;5(1):54-9 [1581537.001]
  • [Cites] Drug Metab Dispos. 2000 Oct;28(10 ):1176-83 [10997936.001]
  • [Cites] Pharmacol Ther. 1997;73(1):67-74 [9014207.001]
  • [Cites] J Thromb Haemost. 2007 Jul;5(7):1545-51 [17456192.001]
  • [Cites] Xenobiotica. 2007 Aug;37(8):884-901 [17701835.001]
  • [Cites] Circulation. 2009 May 19;119(19):2553-60 [19414633.001]
  • [Cites] Curr Med Res Opin. 2009 Aug;25(8):1821-9 [19530977.001]
  • [Cites] J Clin Pharmacol. 2010 Feb;50(2):126-42 [19948947.001]
  • [Cites] N Engl J Med. 2007 Nov 15;357(20):2001-15 [17982182.001]
  • [Cites] Rapid Commun Mass Spectrom. 2007;21(2):169-79 [17154350.001]
  • [Cites] Nat Clin Pract Cardiovasc Med. 2006 Jul;3(7):387-95 [16810174.001]
  • [Cites] Xenobiotica. 2008 Sep;38(9):1240-51 [18720283.001]
  • [Cites] Circulation. 2008 Jan 15;117(2):261-95 [18079354.001]
  • (PMID = 21053990.001).
  • [ISSN] 1179-1926
  • [Journal-full-title] Clinical pharmacokinetics
  • [ISO-abbreviation] Clin Pharmacokinet
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Piperazines; 0 / Platelet Aggregation Inhibitors; 0 / Purinergic P2Y Receptor Antagonists; 0 / Thiophenes; G89JQ59I13 / Prasugrel Hydrochloride
  •  go-up   go-down


21. Chihara D, Oki Y, Ine S, Kato H, Onoda H, Taji H, Kagami Y, Yamamoto K, Morishima Y: Primary gastric diffuse large B-cell Lymphoma (DLBCL): analyses of prognostic factors and value of pretreatment FDG-PET scan. Eur J Haematol; 2010 Jun;84(6):493-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastric diffuse large B-cell Lymphoma (DLBCL): analyses of prognostic factors and value of pretreatment FDG-PET scan.
  • OBJECTIVES: We report a single institution experience with gastric diffuse large B-cell lymphoma (DLBCL) in an attempt to evaluate the roles of different treatment modalities, to assess the value of pretreatment positron emission tomography (PET) scan, and to identify potential prognostic factors.
  • METHODS: Among 384 patients diagnosed with DLBCL between 1995 and 2008, 75 patients had primary gastric DLBCL and were reviewed and analyzed.
  • Pretreatment PET scan was highly sensitive in detecting gastric lesions except stage I gastric DLBCL without detectable mass by CT or gastroscopy.
  • As a general rule, patients with limited-stage disease were treated with three times of CHOP (with or without rituximab) and radiotherapy, and those with advanced-stage disease were treated with eight cycles of CHOP (with or without rituximab), and radiotherapy was given to residual diseases after chemotherapy.
  • Multivariate analysis revealed that low albumin, hemoglobin <12.0 g/dL, and treatment without rituximab were independently associated with shorter OS.
  • CONCLUSION: We showed the survival benefit of rituximab and potential prognostic value of pretreatment hemoglobin and serum albumin levels in gastric DLBCL.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / radionuclide imaging. Stomach Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Fluorine Radioisotopes. Fluorodeoxyglucose F18. Hemoglobins / metabolism. Humans. Male. Middle Aged. Positron-Emission Tomography. Prednisone / administration & dosage. Prognosis. Radiopharmaceuticals. Rituximab. Serum Albumin / metabolism. Survival Analysis. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20148943.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Fluorine Radioisotopes; 0 / Hemoglobins; 0 / Radiopharmaceuticals; 0 / Serum Albumin; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


22. Tang CC, Shih LY, Chen PC, Chen TC: Simultaneous occurrence of gastric adenocarcinoma and low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Chang Gung Med J; 2002 Feb;25(2):115-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous occurrence of gastric adenocarcinoma and low-grade gastric lymphoma of mucosa-associated lymphoid tissue.
  • Gastric adenocarcinoma developing concomitantly with a gastric lymphoma of the mucosa-associated lymphoid tissue (MALT) type is rare.
  • Herein, we report a case with a synchronous primary gastric MALT lymphoma and an early adenocarcinoma of the stomach.
  • A 72-year-old patient with initial presentation of weight loss was found with endoscopy to have a large tumor mass in the gastric body.
  • Pathologic examination of biopsies revealed a low-grade MALT lymphoma for which chemotherapy with cyclophosphamide, vincristine, and prednisolone was administered.
  • A gastric adenocarcinoma was found at a different site in the of stomach 3 months after cessation of chemotherapy when there was still residual MALT lymphoma in the stomach.
  • Infection with Helicobacter pylori (H. pylori) was detected once in the repeated endoscopic gastric biopsies.
  • The occurrence of both gastric MALT lymphoma and gastric adenocarcinoma was reviewed and the association of H. pylori infection with both malignancies is discussed.

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11952271.001).
  • [ISSN] 2072-0939
  • [Journal-full-title] Chang Gung medical journal
  • [ISO-abbreviation] Chang Gung Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


23. Aoyama M, Aoki T, Matsuura Y, Yamanoi T, Watanabe A, Saitou N, Honma M, Ishikawa T, Kodama N, Yamamoto T: [Dramatic but temporary improvements in a case of CNS intravascular malignant lymphomatosis]. Rinsho Shinkeigaku; 2003 Jan-Feb;43(1-2):6-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 54-year-old man with a past history of gastric malignant lymphoma treated by the total gastrectomy and the chemotherapy, developed bilateral sudden deafness one year later.
  • Although the imaging studies of the spinal cord were negative, the myelopathic symptoms resolved dramatically after a course of pulse dose methylprednisolone therapy.
  • However, he soon developed an abnormal behavior and mental deterioration in 3 weeks.
  • The patient remarkably responded to biweekly CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) therapy in terms of regaining the mental alertness and improved hearing.
  • However, the CHOP therapy was prematurely interrupted prior to completion because of infective arthritis.
  • This case was of interest because a solid gastric lymphoma appears to have transformed into the form of intravascular lymphomatosis without mass formations or leukemic changes.
  • Therefore, the therapeutic intervention may dramatically improve the symptoms due to IML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Vascular Neoplasms / drug therapy
  • [MeSH-minor] Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Male. Middle Aged. Prednisolone / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12820543.001).
  • [ISSN] 0009-918X
  • [Journal-full-title] Rinshō shinkeigaku = Clinical neurology
  • [ISO-abbreviation] Rinsho Shinkeigaku
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  • [Number-of-references] 20
  •  go-up   go-down


24. Koczka CP, Goodman AJ: Gastric amyloidoma in patient after remission of Non-Hodgkin's Lymphoma. World J Gastrointest Oncol; 2009 Oct 15;1(1):93-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric amyloidoma in patient after remission of Non-Hodgkin's Lymphoma.
  • Amyloidosis is commonly systemic, occasionally organ-limited, and rarely a solitary localized mass.
  • The latter, commonly referred to as tumoral amyloidosis, is described as occurring in nearly every organ/tissue.
  • Only a few reports of gastric amyloidosis exist today.
  • His medical history included Non-Hodgkin's Lymphoma diagnosed five years ago, status-post six rounds of cyclophosphamide, adriamycin, vincristine, prednisone chemotherapy, and currently was in remission.
  • On computed tomography scan of the abdomen, thickening and calcification of the gastric wall was noted along with pneumatosis.
  • On esophagogastroduodenoscopy, a large circumferential friable mass was seen from the gastroesophageal junction to the body.
  • A large non-bleeding 3 cm polyp was also seen in post bulbar area of duodenum.
  • Positron emission tomography scan revealed diffuse gastric mucosa uptake compatible with gastric malignancy without metastatic foci.
  • Treatment for gastric amyloidomas has presently been one of observation or, at most, resection of the amyloid mass.
  • It is not known if our patient required the same approach or if this warranted the re-institution of chemotherapy for Non-Hodgkin's Lymphoma.
  • Until more reports of tumoral amyloidosis are made known, treatment as well as prognosis remain uncertain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160781.001).
  • [ISSN] 1948-5204
  • [Journal-full-title] World journal of gastrointestinal oncology
  • [ISO-abbreviation] World J Gastrointest Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999100
  • [Keywords] NOTNLM ; Amyloidoma / Duodenum / Lymphoma / Non-Hodgkin / Stomach
  •  go-up   go-down


25. Yang SE, Jin JY, Song CW, Park JC, Lee JI, Kim W, Kim J, Lee HG: Gastrosplenic Fistula Complicated in a Patient with Non- Hodgkin's Lymphoma. Cancer Res Treat; 2002 Apr;34(2):153-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most gastrosplenic fistulae caused by lymphoma eventually close following chemotherapy, although splenectomy should be performed to avoid further complications.
  • He was admitted to our hospital because of LUQ mass.
  • On the abdominal CT, a splenic mass with central necrosis and gas was discovered.
  • The biopsy specimen of the stomach and spleen displayed diffuse, large B cell type non-Hodgkin's lymphoma.
  • After one cycle of CHOP chemotherapy, the LUQ mass was markedly regressed although the gastrosplenic fistula was still present on the follow-up CT.
  • The fistula was treated by splenectomy and a partial resection of gastric fundus.
  • Follow-up chemotherapy was continued after surgery.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 26680857.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


26. [Tuberculosis in compromised hosts]. Kekkaku; 2003 Nov;78(11):717-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Many new findings and useful reports for practical medical treatment are submitted; why these compromised hosts are predisposed to tuberculosis, tuberculosis diagnostic and remedial notes of those compromised hosts etc.
  • In 1980, Saiki and co-workers reported that host defense and delayed-type hypersensitivity response to M. tuberculosis was hampered in a mouse DM model established by injecting streptozotocin (Infect Immun.
  • Patients who have undergone gastric resection are considered at increased risk of developing pulmonary tuberculosis.
  • Of 654 pulmonary tuberculosis patients admitted to National Chiba-Higashi Hospital from January 1999 to December 2001, 55 patients (31-84 years old, mean 63.5 +/- 12.5 years, 48 males and 7 females) had the history of gastric resection.
  • The mean age of gastric resection was 50.2 +/- 16.6 years, and the mean interval from gastrectomy to pulmonary tuberculosis was 13.6 +/- 11.0 years.
  • Gastrectomy was done due to carcinoma of the stomach in 31 cases, gastric and/or duodenal ulcer in 21 cases, adenomatous polyp in two cases, and accidental injury in one case.
  • Body weight, Body Mass Index, Prognostic Nutritional Index (PNI; 10x serum albumin concentration +0.005 x peripheral lymphocyte count) which was proposed by Onodera, serum albumin level and serum total cholesterol level were lower in the gastrectomy group than in the non-gastrectomy group.
  • I calculated the odds of tuberculosis among gastrectomy patients to be 3.8 times that of appropriate controls.
  • People with large reaction against the tuberculin test were better prognosis than those with smaller reaction.
  • It is easy to stay in the leaching lesion so that anti-tuberculosis drugs are much effective, and the patients recover easily.
  • However, if the treatment is delayed, it is fatally because hematogenous metastasis are easy to occur and become miliary tuberculosis.
  • With AIDS patients with tuberculosis, there are the following problems on the treatment. (1) The adverse reactions by antituberculosis drugs tend to occur in AIDS patients.
  • Eleven of 33 AIDS patients with tuberculosis had the adverse reactions (skin rash, fever, liver dysfunction) considered to be due to antituberculosis drugs.
  • It is a very large burden for the HIV infected persons to take simultaneously antituberculosis drugs, medicines for opportunistic infections, and anti-HIV medicines.
  • Since many medicines are taken, it is difficult to determine which drug is the cause once an adverse reaction occurs and all medicines should be often stopped. (2) The combined use with rifampicin (RFP) is difficult for the protease inhibitors and nonnuclear acid reverse transcriptase inhibitors.
  • RFP induces cytochrome P-450 in liver, accelerates the metabolism of some concomitant drug agents, and reduces blood concentration them remarkably.
  • When starting the two above-mentioned medicines during tuberculosis treatment, RFP should be changed to rifabutin (RFB) which has less induction of P-450 than RFP.
  • So, the treatment with EFV and RFP is recently chosen.
  • However, the monitor of the blood concentration of EFV is required, and the dose of EFV should be increased if it is a low value. (3) When a highly active antiretroviral therapy (HAART) is given to AIDS patients with tuberculosis, transient worsening of tuberculosis may develop after about two weeks. (ABSTRACT TRUNCATED)

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14672050.001).
  • [ISSN] 0022-9776
  • [Journal-full-title] Kekkaku : [Tuberculosis]
  • [ISO-abbreviation] Kekkaku
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


27. Shi H, Cao D, Wei L, Sun L, Guo A: Primary choriocarcinoma of the liver: a clinicopathological study of five cases in males. Virchows Arch; 2010 Jan;456(1):65-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients presented with a large hepatic mass on ultrasonography that measured 11 cm on average in the greatest diameter.
  • At presentation, the tumor was confined to the liver in two patients and therefore surgically resected.
  • The other three patients presented with extrahepatic metastases on imaging study and therefore only received chemotherapy.
  • All five patients died from the tumor within 2 to 8 months.
  • None of the patients had any evidence of a testicular tumor or scar after examination of the entirely submitted testes.
  • No tumor was observed in central nervous system, mediastinum, or other organs other than described above.
  • Grossly, the primary tumors were large, soft, hemorrhagic, and with foci of necrosis.
  • Histologically, the tumors were composed of mononucleated trophoblastic cells with round nuclei, clear cytoplasm, and prominent nucleoli admixed with large, multinucleated syncytiotrophoblastic cells.
  • Immunohistochemically, tumor cells were strongly positive for keratin, HCG, and focally positive for human placental lactogen.

  • Genetic Alliance. consumer health - Choriocarcinoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thorac Cardiovasc Surg. 1985 Jun;89(6):826-35 [2987618.001]
  • [Cites] J Surg Oncol. 1987 Jan;34(1):39-42 [2433543.001]
  • [Cites] Prog Neurol Surg. 2009;23:59-75 [19329861.001]
  • [Cites] Am J Surg Pathol. 1997 Sep;21(9):1007-12 [9298876.001]
  • [Cites] Adv Anat Pathol. 2007 Mar;14(2):69-92 [17471115.001]
  • [Cites] Indian J Pathol Microbiol. 2003 Oct;46(4):658-9 [15025371.001]
  • [Cites] J Clin Pathol. 1998 Dec;51(12):939-40 [10070339.001]
  • [Cites] Acta Radiol Oncol. 1984;23(4):239-47 [6093440.001]
  • [Cites] Pathol Int. 2006 Jul;56(7):402-7 [16792550.001]
  • [Cites] Semin Diagn Pathol. 1990 Nov;7(4):266-84 [2178277.001]
  • [Cites] Virchows Arch. 1998 Jul;433(1):93-6 [9692832.001]
  • [Cites] Am J Surg Pathol. 2006 Jul;30(7):858-65 [16819328.001]
  • [Cites] Cancer. 1990 Jun 15;65(12):2681-5 [2160316.001]
  • [Cites] Hinyokika Kiyo. 2008 Apr;54(4):293-6 [18516924.001]
  • [Cites] Pediatr Radiol. 2004 Oct;34(10):820-3 [15378219.001]
  • [Cites] J Reprod Med. 2008 May;53(5):369-72 [18567286.001]
  • [Cites] Pediatr Pathol. 1993 Nov-Dec;13(6):723-30 [8108292.001]
  • [Cites] Cancer. 1993 Sep 15;72(6):1894-901 [7689921.001]
  • [Cites] J Postgrad Med. 1987 Oct;33(4):219-21 [3449627.001]
  • [Cites] Am J Med. 1971 Sep;51(3):416-22 [4940262.001]
  • [Cites] Hepatogastroenterology. 2001 Mar-Apr;48(38):424-6 [11379323.001]
  • [Cites] Transpl Int. 2008 Jun;21(6):598-601 [18363574.001]
  • [Cites] Int J Gynaecol Obstet. 2005 Feb;88(2):158-9 [15694099.001]
  • [Cites] Hum Pathol. 2004 Nov;35(11):1427-30 [15668903.001]
  • [Cites] Gastric Cancer. 2005;8(3):178-85 [16086121.001]
  • [Cites] Pediatr Blood Cancer. 2007 Jul;49(1):99-102 [16206190.001]
  • [Cites] Gastroenterol Clin Biol. 2007 Oct;31(10):854-7 [18166865.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1756-8 [15118001.001]
  • [Cites] Ann Diagn Pathol. 2009 Apr;13(2):96-100 [19302957.001]
  • [Cites] Pathol Res Pract. 1992 Apr;188(3):375-7; discussion 378-9 [1626001.001]
  • [Cites] J Urol. 2002 Apr;167(4):1789 [11912416.001]
  • [Cites] Br J Urol. 1983 Aug;55(4):440-4 [6883052.001]
  • [Cites] J Clin Oncol. 2008 Dec 10;26(35):5813-4 [19001337.001]
  • (PMID = 20013345.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Chorionic Gonadotropin; 0 / Ki-67 Antigen; 9035-54-5 / Placental Lactogen
  •  go-up   go-down


28. Rajpal S, Warren RS, Alexander M, Yeh BM, Grenert JP, Hintzen S, Ljung BM, Bergsland EK: Pancreatoblastoma in an adult: case report and review of the literature. J Gastrointest Surg; 2006 Jun;10(6):829-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An abdominal computed tomography scan demonstrated a 12 x 12-cm pancreatic mass involving the greater curvature of the stomach and multiple hypervascular hepatic metastases.
  • An initial fine needle aspiration of the pancreatic mass was nondiagnostic, and a subsequent fine needle aspiration of a liver mass was read as metastatic acinar cell carcinoma.
  • The patient underwent a palliative resection for tumor-associated pain and gastrointestinal hemorrhage that revealed a large pancreatic tumor invading through the full thickness of the colon at the splenic flexure and adherent to the posterior gastric wall.
  • The pathology from the distal pancreatectomy, splenectomy, partial gastrectomy, partial colectomy, and cholecystectomy unexpectedly supported a diagnosis of pancreatoblastoma with evidence for squamoid corpuscles as well as areas of acinar formation.
  • Despite multiple chemotherapy regimens, the patient's disease continued to progress in the liver and the lungs.
  • During the course of his therapy, the patient's serum alpha-fetoprotein levels and serum lipase levels rose concurrently, suggesting tumor-associated production of both of these factors.
  • [MeSH-minor] Abdominal Pain / etiology. Biopsy, Fine-Needle. Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / secondary. Disease Progression. Humans. Immunohistochemistry. Liver Neoplasms / secondary. Male. Middle Aged. Nausea / etiology. Neoplasm Invasiveness. Satiety Response. Splenic Vein / diagnostic imaging. Splenic Vein / pathology. Stomach / pathology. Tomography, X-Ray Computed. Vomiting / etiology

  • Genetic Alliance. consumer health - Pancreatoblastoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 1995 Jun;119(6):547-51 [7605173.001]
  • [Cites] Am J Gastroenterol. 1996 Sep;91(9):1841-4 [8792711.001]
  • [Cites] Hum Pathol. 1992 Jul;23(7):828-30 [1377164.001]
  • [Cites] Am J Pathol. 1993 Sep;143(3):685-98 [8362971.001]
  • [Cites] Gastroenterol Clin Biol. 1997;21(11):880-3 [9587540.001]
  • [Cites] J Pediatr Surg. 2002 Jun;37(6):887-92 [12037756.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4673-8 [12488412.001]
  • [Cites] Med Pediatr Oncol. 2001 Jul;37(1):47-52 [11466723.001]
  • [Cites] Pancreatology. 2004;4(5):441-51; discussion 452-3 [15256806.001]
  • [Cites] Radiol Med. 2002 Jan-Feb;103(1-2):119-22 [11859308.001]
  • [Cites] Arch Pathol Lab Med. 2003 Nov;127(11):1501-5 [14567752.001]
  • [Cites] Virchows Arch. 1994;424(5):485-90 [8032529.001]
  • [Cites] Arch Pathol Lab Med. 1986 Jul;110(7):650-2 [3013120.001]
  • [Cites] Chirurg. 2001 Jul;72(7):806-11 [11490758.001]
  • [Cites] Radiology. 2000 Feb;214(2):476-82 [10671596.001]
  • [Cites] Adv Anat Pathol. 2001 May;8(3):144-59 [11345238.001]
  • [Cites] J Gastroenterol. 1998 Oct;33(5):761-5 [9773947.001]
  • [Cites] World J Surg. 1998 Aug;22(8):879-82 [9673563.001]
  • [Cites] Am J Surg Pathol. 1995 Dec;19(12):1371-89 [7503360.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1619-27 [11696422.001]
  • [Cites] Hepatogastroenterology. 2001 Sep-Oct;48(41):1340-2 [11677959.001]
  • (PMID = 16769539.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


29. Morse M, Kessler J, Albrecht S, Kim R, Thakur R, Nthobatsang R, Radisowa K, Maunatlala C, Yang W, Macgregor RR, Friedman H: Induced sputum improves the diagnosis of pulmonary tuberculosis in hospitalized patients in Gaborone, Botswana. Int J Tuberc Lung Dis; 2008 Nov;12(11):1279-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: To evaluate induced sputum, gastric content, blood and urine specimens to improve PTB diagnosis in patients not diagnosed by expectorated sputum AFB smears.
  • DESIGN: Patients admitted to the medical wards of a large public hospital in Gaborone, Botswana, were prospectively enrolled if they had symptoms consistent with PTB, an abnormal chest radiograph, were treated empirically with anti-tuberculosis chemotherapy or had no improvement on antibiotics, and had a non-productive cough or AFB smear-negative sputum.
  • Induced sputum was stained for AFB and Mycobacterium tuberculosis cultures were performed on induced sputum, gastric contents, urine and blood.
  • Fifty-seven (41%) had PTB based on positive cultures from one or more sites, including 48 (84%) from induced sputum, 17 (30%) urine, 13 (23%) gastric contents and 7 (12%) blood.
  • CONCLUSION: Induced sputum cultures greatly enhanced M. tuberculosis detection in patients with a high prevalence of HIV/AIDS in a hospital without access to bronchoscopy.
  • [MeSH-major] Diagnostic Errors / prevention & control. Mass Screening / methods. Sputum / microbiology. Tuberculosis, Pulmonary / prevention & control

  • Genetic Alliance. consumer health - Tuberculosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18926038.001).
  • [ISSN] 1027-3719
  • [Journal-full-title] The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease
  • [ISO-abbreviation] Int. J. Tuberc. Lung Dis.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / P30 AI45008
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  •  go-up   go-down


30. Ma J, Kimura W, Takeshita A, Hirai I, Moriya T, Mizutani M: Neuroendocrine carcinoma of the stomach with peripancreatic lymph node metastases successfully treated with pancreaticoduodenectomy. Hepatogastroenterology; 2007 Oct-Nov;54(79):1945-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neuroendocrine carcinoma of the stomach is an uncommon tumor, usually associated with highly malignant biological behavior and extremely poor prognosis.
  • An upper gastrointestinal endoscopy revealed a 4x4-cm fungating tumor with its fundus locating mainly in the duodenal bulbus and extending to the gastric antrum, and tumor biopsy revealed the histological findings of adenocarcinoma.
  • Computed tomography (CT) showed a large mass in the duodenal bulbus with regional lymph node metastases.
  • Histopathologically, the origin of the primary tumor was considered as a gastric origin, and the tumor was composed of diffused small cells with a moderate mitotic index and occasional rosette formation.
  • Immunohistochemical investigations of the neoplastic cells confirmed the tumor to be neuroendocrine carcinoma.
  • Adjuvant chemotherapy with TS-1 was administered on an out-patient basis 6 weeks after the operation.
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Duodenum / pathology. Endoscopy, Gastrointestinal. Humans. Immunohistochemistry. Lymph Node Excision. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Pancreaticoduodenectomy. Silicates / therapeutic use. Titanium / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TITANIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18251134.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Silicates; 12067-57-1 / titanium silicide; D1JT611TNE / Titanium
  •  go-up   go-down


31. Foti R, Fazio P, Lizzio G, Leonardi R: [Angioedema: first manifestation of non-Hodgkin's lymphoma]. Ann Ital Med Int; 2002 Jul-Sep;17(3):185-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Abdominal ultrasonography and computed tomography showed two solid splenic masses infiltrating the greater curvature of the stomach and a 2 cm aortic lymph node.
  • A diagnosis of anaplastic large-cells lymphoma CD30+, anaplastic lymphoma kinase negative was made.
  • The disappearance of the neoplastic gastric infiltration and the decrease in size of the aortic lymph node and splenic mass were achieved after chemotherapy.
  • [MeSH-major] Angioedema / etiology. Autoimmune Diseases / etiology. Complement C1 Inactivator Proteins / deficiency. Complement C1 Inactivator Proteins / immunology. Lymphoma, Large B-Cell, Diffuse / complications
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Autoantibodies / immunology. Biomarkers, Tumor / blood. Bleomycin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Humans. Lymph Nodes / pathology. Male. Middle Aged. Neoplasm Proteins / analysis. Prednisone / administration & dosage. Spleen / pathology. Stomach / pathology. Tomography, X-Ray Computed. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Autoimmune Diseases.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Ital Med Int. 2002 Jul-Sep;17(3):143-5 [12402660.001]
  • (PMID = 12402667.001).
  • [ISSN] 0393-9340
  • [Journal-full-title] Annali italiani di medicina interna : organo ufficiale della Società italiana di medicina interna
  • [ISO-abbreviation] Ann. Ital. Med. Int.
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / Complement C1 Inactivator Proteins; 0 / Neoplasm Proteins; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; VACOP-B protocol
  •  go-up   go-down


32. Yamamoto S, Tanaka Y, Ito T, Aono T, Morimoto Y, Kitagawa T, Kurihara Y: Weekly paclitaxel for a patient with advanced gastric cancer. Gastric Cancer; 2003;6(2):117-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly paclitaxel for a patient with advanced gastric cancer.
  • A 56-year-old woman diagnosed with gastric cancer was admitted to our hospital for operation on May 15, 2001.
  • The tumor formed a large mass from the antrum to the head of the pancreas, and cancer cells were detected in the ascitic fluid microscopically.
  • On July 17, a new regimen, of 4-week courses of chemotherapy, with weekly administrations of 65 mg/m2 of paclitaxel, along with premedication for 3 weeks, followed by 1 week of rest, was started.
  • After paclitaxel was started, gastric fiberscopy and computed tomography (CT) scan showed reduction of the tumor.
  • Neuropathy was slight and no treatment was needed.
  • Now, after 1 year, 11 courses of chemotherapy have been administered at the outpatient clinic.
  • These results suggest weekly administration of paclitaxel to be a promising treatment for advanced gastric cancer with peritoneal dissemination.
  • The therapeutic efficacy should be confirmed by further clinical trials.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / therapeutic use. Paclitaxel / therapeutic use. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Female. Gastric Mucosa / drug effects. Gastric Mucosa / pathology. Gastric Mucosa / radiography. Humans. Middle Aged. Radiography, Abdominal. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12884850.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 14
  •  go-up   go-down


33. Peruzzi P, Ray-Chaudhuri A, Slone WH, Mekhjian HS, Porcu P, Chiocca E: Reversal of neurological deficit after chemotherapy in BCL-6-positive neurolymphomatosis. Case report. J Neurosurg; 2009 Aug;111(2):247-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reversal of neurological deficit after chemotherapy in BCL-6-positive neurolymphomatosis. Case report.
  • Neurolymphomatosis, the infiltration of the peripheral nervous system (PNS) by malignant lymphatic cells, is a rare condition whose prognosis and treatment are not fully characterized.
  • Subsequent MR imaging of his right brachial plexus showed an enhancing mass of the posterior cord of the plexus that encroached on the other cords.
  • Positron emission tomography confirmed the presence of a hypermetabolic lesion in the right axillary region and also detected an asymptomatic hot spot in the gastric wall.
  • Biopsy of the gastric lesion demonstrated a CD20+, diffuse large B-cell lymphoma that was immunohistochemically positive for BCL-6 and negative for p16.
  • Follow-up MR imaging and PET of the plexus showed complete radiological response after 3 months of treatment, as demonstrated by normalization of brachial plexus caliber, contrast enhancement, and metabolic activity.
  • Twenty-eight months after symptom onset and 20 months after beginning therapy, the patient was disease-free, had recovered most upper extremity neurological function, and had only minimal remaining weakness of the right wrist and finger extension.
  • [MeSH-major] Brachial Plexus Neuropathies / drug therapy. Lymphoma, B-Cell / drug therapy. Peripheral Nervous System Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Humans. Magnetic Resonance Imaging. Male. Methotrexate / administration & dosage. Prednisone / administration & dosage. Proto-Oncogene Proteins c-bcl-6 / analysis. Rituximab. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Brachial Plexus Injuries.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19216652.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Proto-Oncogene Proteins c-bcl-6; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; EPOCH protocol
  •  go-up   go-down


34. Jacquemart C, Guidi O, Etienne I, Delrez R, Forget P, Dresse MF, Depas G, de Leval L, Hoyoux C: Pediatric gastric lymphoma: a rare entity. J Pediatr Hematol Oncol; 2008 Dec;30(12):984-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric gastric lymphoma: a rare entity.
  • Primary gastric lymphoma is a rare event in childhood.
  • We describe a 13-year-old boy with gastric Burkitt-like lymphoma localized in the fundus.
  • Biopsies obtained by ultrasound gastroscopy proved the diagnosis; F-fluorodeoxyglucose-positron emission tomography detected an isolated large gastric hypermetabolic mass.
  • According to the international FAB/LMB 96 trial, the patient was treated with chemotherapy alone and is in first complete remission 2(1/2) years after diagnosis.
  • [MeSH-minor] Adolescent. Fluorodeoxyglucose F18. Helicobacter Infections / diagnosis. Helicobacter Infections / drug therapy. Helicobacter pylori / isolation & purification. Humans. Male. Positron-Emission Tomography. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19131798.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


35. Gluth MB, Orvidas LJ: Bilateral cystic parotid masses and a hypopharyngeal mass: a case report and review of mucosa-associated lymphoid tissue lymphoma in the head and neck. Am J Otolaryngol; 2005 Mar-Apr;26(2):135-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral cystic parotid masses and a hypopharyngeal mass: a case report and review of mucosa-associated lymphoid tissue lymphoma in the head and neck.
  • Mucosa-associated lymphoid tissue (MALT) lymphoma is a low-grade B-cell lymphoma that was first described in gastric mucosa.
  • We describe an 83-year-old man with a large painless facial swelling; he was otherwise asymptomatic.
  • On examination, bilateral parotid masses and a mass in the hypopharynx were found.
  • The patient was treated with single-agent chemotherapy and had a good initial response.
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Chlorambucil / therapeutic use. Humans. Male. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15742269.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 18D0SL7309 / Chlorambucil
  •  go-up   go-down






Advertisement